Table 2. Changes of MEG3 expression level in different mouse models.
Reference | Cancer Type | Country | Samples | Number of samples case/control | MEG3 Level | Methods | Potential function and mechanism |
---|---|---|---|---|---|---|---|
Chunharojrith et al., 2015 [80] | NFAs | USA | Nude mice | 5/5 | Down | RT-PCR | MEG3 causes cell cycle arrest at the G1 phase |
Luo et al., 2015 [60] | PC | China | Nude mice | 5/5(pCDNA /pCDNA-MEG3) | Down | qRT-PCR | MEG3 inhibits the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase |
Yin et al., 2015 [54] | CRC | China | Nude mice | 3/3 | Down | qRT-PCR | The proliferation index ki-67 is significantly decreased in the MEG3-transfected tumor cells. In addition, the cleaved caspase-3 level is increased. |
Zhuo et al., 2015 [34] | HCC | China | Nude mice | 5/5 | Down | qRT-PCR | MEG3 inhibits proliferation and induces apoptosis through the accumulation of TP53. |
Liu et al., 2015 [38] | LAD | China | Nude mouse xenograft model | 6/6 (pCDNA-MEG3/ empty vector + cisplatin) | Down | qRT-PCR | MEG3 overexpression increases the in vivo chemosensitivity of LAD cells to cisplatin. |
Modali et al., 2015 [62] | Insulinomas | USA | Mice | 7/6 | Down | qRT-PCR | DNA demethylating drugs reduce mouse insulinoma cell proliferation and restore MEG3 expression. |
Lu et al., 2013 [44] | NSCLC | China | Nude mice | 5/5 | Down | qRT-PCR | Overexpression of MEG3 could inhibit tumor growth in vivo. |
Lempiäinen et al., 2013 [82] | LT | UK | PB treatment Mice | 5 Pairs | Down | qRT-PCR | PB induces MEG3 expression in glutamine synthetase positive hypertrophic hepatocytes. |
Gordon et al., 2010 [81] | PA | USA | Nude mice | 5 Pairs | Lost | qRT-PCR | Increased expression of angiogenic genes in the brains of MEG3-null mice. |
Kawakami et al., 2006 [46] | RCC | Japan | Nude mice | 5 Pairs | Lost | qRT-PCR | Reintroduction of DLK1 into DLK1-null RCC cell suppresses tumor growth in nude mice. |
Abbreviations: CRC; Colorectal cancer; HCC, Hepatocellular Carcinoma; LAD; lung adenocarcinoma, PA, pituitary adenomas; RCC, Renal Cell Carcinoma; LT, Liver Tumor; NSCLC, Non-small cell lung cancer.; NFAs, non-functioning pituitary adenomas.